title: Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis.
abstract: OBJECTIVE
  To present moxifloxacin as an alternative treatment option to ethambutol in an anti-tubercular therapy (ATT) regime in patients with presumed ocular tuberculosis (TB).
  
  
  METHODS
  We identified all cases in our hospital referred for treatment of presumed ocular TB between 2009 and 2013. Age, gender, ophthalmic examination, blood tests, treatment regimens, adverse drug reactions, and outcomes were collected and analyzed for the patients who had moxifloxacin as part of their ATT.
  
  
  RESULTS
  Forty-three cases of presumed ocular TB were treated with moxifloxacin as a part of ATT. Mean age was 44.18 ± 12.47 years; 62.8% were male. A response to treatment, with no evidence of disease recurrence, was seen in 72.1% of cases. Shortened ATT duration was associated with increased risk of treatment failure (p = 0.02, 95% CI: -0.77 to -0.00).
  
  
  CONCLUSIONS
  Moxifloxacin can be considered as a safe and effective alternative to ethambutol for the treatment of presumed ocular TB.
authors.affiliation: a Barts Health NHS Trust, TB Service , London , UK .
authors.forename: Jessica
authors.initials: J
authors.lastname: Potter
authors.affiliation: b Moorfields Eye Hospital, NHS Foundation Trust , London , UK .|c Biomedical Research Centre, UCL Institute of Ophthalmology , London , UK , and.|d National Healthcare Group Eye Institute, Tan Tock Seng Hospital , Singapore.
authors.forename: Rupesh
authors.initials: R
authors.lastname: Agrawal
authors.affiliation: a Barts Health NHS Trust, TB Service , London , UK .
authors.forename: Claire
authors.initials: C
authors.lastname: Barraclough
authors.affiliation: b Moorfields Eye Hospital, NHS Foundation Trust , London , UK .
authors.forename: Farzana
authors.initials: F
authors.lastname: Rahman
authors.affiliation: b Moorfields Eye Hospital, NHS Foundation Trust , London , UK .
authors.forename: Mark
authors.initials: M
authors.lastname: Westcott
authors.affiliation: b Moorfields Eye Hospital, NHS Foundation Trust , London , UK .|c Biomedical Research Centre, UCL Institute of Ophthalmology , London , UK , and.
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Pavesio
authors.affiliation: a Barts Health NHS Trust, TB Service , London , UK .
authors.forename: Veronica
authors.initials: V
authors.lastname: White
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D000529:Complementary Therapies; D004977:Ethambutol / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D014374:Tuberculin Test; D014392:Tuberculosis, Ocular / Q000175:diagnosis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D024841:Fluoroquinolones; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D004977:Ethambutol; D007372:Interferons; D000077266:Moxifloxacin
keywords: Anti-tubercular therapy (ATT); drug-resistant TB; duration of ATT; ethambutol; moxifloxacin; presumed ocular tuberculosis